Management Team

Broadwater Health's management team is driven by their expertise, entrepreneurial spirit and passion.

Dr Conal Perrett

Chairman

Conal is responsible for the company’s vision, strategy, business ethics and culture.

18 Week Support was borne out of Conal’s vision to support and expedite patient access to medical care in the UK. He is passionate about improving efficiency and outcomes in healthcare.

As a Consultant Dermatologist & Dermatological Surgeon at University College London Hospitals NHS Trust (UCLH) and Royal Brompton & Harefield NHS Trust, he has contributed to Dermatology and skin cancer services in the NHS for many years. He has served as the Skin Cancer Lead at UCLH, the Mohs Micrographic Surgery Lead to the London Cancer Skin Pathway Board and is the Dermatologist to the London Sarcoma Service.

Awarded a prestigious Cancer Research UK Fellowship, he subsequently received his PhD in 2008 for his research into skin cancer. He continues his commitment to research and medical education as an Honorary Senior Lecturer at University College London (UCL), where he supervises PhD students and has served as a PhD and MSc examiner for the University of London. He is on the Board of the British Society for Skin Care in Immunocompromised Individuals (BSSCII) and is also an alumnus of Goldman Sachs International.

Paul Reith

CEO

Paul has over 25 years’ experience in healthcare investment banking and private equity. Paul has advised International Medtech and Pharmaceutical clients such as Actavis (Teva), AstraZeneca plc, Sanofi, Shire plc and Zeltia. Paul also has myriad experience advising International private equity firms such as KKR, TPG and others on healthcare transactions.

Paul’s experience was gained at investment banks such as Barings and HSBC, where he was a senior member of the Global Healthcare group. Latterly his roles at Symphony Advisors and UK private equity firm Clearbrook Capital have seen him engage with both developed and emerging markets healthcare companies across Medtech, eHealth, generics and distribution sectors.